Search

Displaying results 1341 - 1350 of 10000 in total
  1. Drug

    Moexipril

    go.drugbank.com/drugs/DB00691
    ApprovedInvestigational

    It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems. … Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension).

  2. Drug

    Colfosceril palmitate

    go.drugbank.com/drugs/DB09114
    ApprovedWithdrawn

    [T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990.[L1109] Nowadays colfosceril palmitate is under the state of canceled post-marketing.

  3. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    Although corticosteroids effectively slow disease progression in both DMD and BMD patients, they do not address the underlying molecular pathogenesis. … Casimersen is currently marketed under the tradename AMONDYS 45™ by Sarepta Therapeutics, Inc.[L32118]

  4. Drug

    Naftifine

    go.drugbank.com/drugs/DB00735
    Approved

    Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum

  5. Drug

    Velmanase alfa

    go.drugbank.com/drugs/DB12374
    ApprovedInvestigational

    [A244509] In February 2023, the FDA also approved velmanase alfa for the same indication.[L45295] Velmanase alfa is currently not approved in Canada. … [L39744] It was granted marketing authorization by the European Commission in March 2018 under the market name Lamzede [L39754] as the first human recombinant form of alpha-mannosidase for the treatment

  6. Drug

    Moxonidine

    go.drugbank.com/drugs/DB09242
    ApprovedInvestigationalWithdrawn

    It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. … Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension.

  7. Drug

    Omidubicel

    go.drugbank.com/drugs/DB17132
    ApprovedInvestigational

    In addition, the fact that 39% of the study's cohort were non-White patients highlights the importance of this type of treatment in key demographics with low donor availability. … In this group of patients, umbilical cord blood can be used as an alternative cell source since there is a lower risk of graft failure or graft-versus-host disease, even with low-grade HLA-matching.

  8. Drug

    Benactyzine

    go.drugbank.com/drugs/DB09023
    ApprovedWithdrawn

    Benactyzine is no longer widely used in medicine, although it is still a useful drug for scientific research. It does not possess any antihistamine properties.

  9. Drug

    Oxethazaine

    go.drugbank.com/drugs/DB12532
    ApprovedWithdrawn

    low pH levels. … [L1113] It is also in the list of approved derivatives of herbal products by the EMA.[L2816]

  10. Drug

    Rimantadine

    go.drugbank.com/drugs/DB00478
    Approved

    An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.